User profiles for Kurt W. Prins
Kurt PrinsUniversity of Minnesota Verified email at umn.edu Cited by 1915 |
Dystrophin is a microtubule-associated protein
KW Prins, JL Humston, A Mehta, V Tate… - Journal of Cell …, 2009 - rupress.org
Cytolinkers are giant proteins that can stabilize cells by linking actin filaments, intermediate
filaments, and microtubules (MTs) to transmembrane complexes. Dystrophin is functionally …
filaments, and microtubules (MTs) to transmembrane complexes. Dystrophin is functionally …
Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis
Objectives : This study sought to evaluate the effects of beta-blocker withdrawal in acute
decompensated heart failure (ADHF). Background : Published reports showed trends for either …
decompensated heart failure (ADHF). Background : Published reports showed trends for either …
Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension
… Author links open overlay panel Kurt W. Prins MD, PhD a , Stephen L. Archer MD b , Marc
Pritzker MD a , Lauren Rose BS a , E. Kenneth Weir MD a , Alok Sharma MD c , Thenappan …
Pritzker MD a , Lauren Rose BS a , E. Kenneth Weir MD a , Alok Sharma MD c , Thenappan …
Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease
Background Patients with pulmonary hypertension caused by chronic lung disease (Group
3 PH ) have disproportionate right ventricle ( RV ) dysfunction, but the correlates and clinical …
3 PH ) have disproportionate right ventricle ( RV ) dysfunction, but the correlates and clinical …
The critical role of pulmonary arterial compliance in pulmonary hypertension
T Thenappan, KW Prins, MR Pritzker… - Annals of the …, 2016 - atsjournals.org
The normal pulmonary circulation is a low-pressure, high-compliance system. Pulmonary
arterial compliance decreases in the presence of pulmonary hypertension because of …
arterial compliance decreases in the presence of pulmonary hypertension because of …
Treatment targets for right ventricular dysfunction in pulmonary arterial hypertension
Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. …
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. …
Repurposing medications for treatment of pulmonary arterial hypertension: what's old is new again
Pulmonary arterial hypertension (PAH) is a rare but lethal disorder caused by several
pathological changes in the pulmonary vasculature. There is endothelial cell dysfunction …
pathological changes in the pulmonary vasculature. There is endothelial cell dysfunction …
Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis
Pulmonary hypertension (PH) complicating chronic obstructive pulmonary disease (COPD-PH)
and interstitial lung disease (ILD-PH) (World Health Organization [WHO] Group III PH) …
and interstitial lung disease (ILD-PH) (World Health Organization [WHO] Group III PH) …
World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology
KW Prins, T Thenappan - Cardiology clinics, 2016 - cardiology.theclinics.com
Pulmonary hypertension (PH) is defined as mean pulmonary arterial pressure(PAP) measured
by right heart catheterization of 25 mm Hg or higher at rest. 1 The most recent World …
by right heart catheterization of 25 mm Hg or higher at rest. 1 The most recent World …
Macrophage–NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension
Rationale: Pulmonary arterial hypertension (PAH) often results in death from right ventricular
failure (RVF). NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin …
failure (RVF). NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin …